This is usually mild but should be reported immediately if it occurs." Ongoing Monitoring At Each Follow-Up Visit: Ask specifically about tingling, numbness, burning sensations Check sensation in hands and feet Document any new symptoms Assess impact on quality of life Consider Dose Reduction If: Mild dysesthesia present but tolerable Patient achieving good weight loss (can afford slightly less efficacy) Symptoms are bothersome but not severe Consider Discontinuation If: Moderate to severe dysesthesia Progressive symptoms despite dose reduction Functional impairment Patient preference to stop Long-Term Unknowns and Research Needs Critical Questions for Future Studies 1
( A ) Mice were treated with semaglutide (10 g/kg) 4 hours before renal artery excision and processing
Considering the uneven sequence conservation and distinct binding modes of GLP-2 and GLP-1, we designed chimeric GLP-2/GLP-1 peptides to explore the molecular basis of ligand specificity
This decline is a major contributor to issues like: Loss of muscle mass Increased body fat Reduced energy and stamina Decreased libido and sexual function Weaker bones Thinning skin and hair Impaired mental clarity and mood The good news
Larger retrospective studies, post-marketing analyses of [glucagon-like peptide-1 agonists], and/or prospective clinical trials would be required to confirm the findings, the firms note read
10.1016/j.fufo.2021.100086 [DOI] [Google Scholar] Bakratsas, G